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Abstract
For the past several decades, retrovirologists from around the world have gathered in late May at
the Cold Spring Harbor Laboratories in New York to present their studies in formal talks and
posters, and to discuss their ongoing research informally at the bar or on the beach. As organizers
of the 2004 Cold Spring Harbor Retroviruses Conference, we have been asked by the editors of
Retrovirology to prepare a review of the meeting for publication on-line. Our goal in this review
is not to provide a detailed description of data presented at the meeting but rather to highlight
some of the significant developments reported this year. The review is structured in a manner that
parallels the organization of the meeting; beginning with the entry phase of the replication cycle,
proceeding with post-entry events, assembly and release, integration, reverse transcription,
pathogenesis/host factors, RNA-related events (transcription, processing, export, and packaging)
and finishing with antivirals. While the most striking developments this year involved post-entry
events and assembly/release, significant progress was made towards elucidating a number of aspects
of the retroviral replication cycle.
Entry
Although no "new" retrovirus receptors were reported at
the meeting, several talks centered on recently discovered
receptors. N. Manel, from the groups that identified
GLUT-1 as an entry receptor for HTLV-1 (N. Taylor, J.-L.
Battini, and M. Sitbon) [1], proposed that part of the path-
ogenic effects of this virus may be due to its perturbation
of glucose metabolism. HTLV-1-infected tissue culture
cells display decreased glucose uptake as a result of enve-
lope (Env) glycoprotein-GLUT-1 interaction. The authors
speculated that if this disruption of glucose metabolism
also occurs in vivo, it might provide insights into the neu-
ronal damage that occurs in some HTLV-1-infected
patients. They also suggested that Env-mediated impair-
ment of GLUT-1 function might contribute to the emer-
gence of preleukemic T cells with new selective advantages
[2].
The co-receptor for feline immunodeficiency virus (FIV),
perhaps the best non-primate model for HIV-1, has also
recently been identified. Work presented by J. Elder
showed that FIV preferentially infects certain subsets of T
cells through interaction with CXCR4 and a 43 kDa pro-
tein. This 43 kDa protein turns out to be CD134, recently
demonstrated to be a receptor for FIV [3]. CD134 was first
described as a member of the tumor necrosis/nerve
growth factor receptor family expressed on activated T
cells. By analogy with the role of CD4 in HIV infection,
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CD134 may target FIV infection to a particular subset of T
cells. Extending the CD4/HIV parallel, CD134 may be the
molecule that initially engages FIV, followed by CXCR4
binding and virus/cell fusion. Elder suggested that CD134
should be referred to as the FIV attachment receptor and
CXCR4 as the entry receptor.
The use of alternative chemokine co-receptors by primary
HIV-1 isolates was discussed by S. Neil from R. Weiss's
group. They proposed that some primary dual-tropic HIV-
1 isolates, especially those isolated from early serocon-
verters, might infect primary astrocytes, endothelial cells
and macrophages through the use of D6, a promiscuous
chemokine receptor highly expressed on these cell types.
They hypothesized that D6 usage to infect endothelial
cells could influence colonization of endothelial compart-
ments and promote placental transmission.
Two groups discussed the risk of pig endogenous retrovi-
rus (PERV) infection of human cells as a potential prob-
lem for xenotransplantation. I. Harrison from the Stoye
lab showed that recombination between different endog-
enous PERVs (A and C), which normally have very low tit-
ers on human cells, could lead to the production of virus
with the capacity to efficiently infect human cells. This tro-
pism change mapped in large part to the Env glycoprotein,
but the Gag-Pol region was also implicated. D. Lavillette
from the Kabat lab presented evidence that wild-type
PERVs, or mutants lacking fully infectious envelopes due
to alterations in a conserved PHQ motif (in SU) required
for γ-retrovirus infection, could bind and enter human
cells when added together with the envelope from gib-
bon-ape leukemia virus, which does infect human cells.
The ability of functional Env glycoproteins from infec-
tious viruses to trans-complement infection by viruses
with mutant envelopes or with restricted tropism on par-
ticular target cells has been reported for several retrovi-
ruses [4,5]. In the case of PERVs, such complementation
has the potential of overcoming host-range and interfer-
ence barriers and could pose a hazard for xenotransplan-
tation.
For a number of years, investigators have attempted to
engineer peptide ligands for cell surface receptors into ret-
roviral Env glycoproteins with the goal of designing retro-
viral gene therapy vectors that would efficiently target
specific cell types. These attempts have been hampered by
low transduction efficiencies. L. Albritton presented work
from her lab demonstrating that incorporation of a pep-
tide sequence into the SU receptor binding site (RBS) may
overcome this problem. Her lab constructed a chimera in
which the RBS of the Moloney murine leukemia virus
(MLV) Env was replaced with the peptide ligand somato-
statin (Sst). Such chimeras efficiently infected human cells
expressing the Sst receptor, but could no longer infect
mouse cells expressing the natural receptor, ATCR1. The
similarity in length of the peptide with the sequence it
replaced, as well as the structural similarity between
ATCR1 and the Sst receptor, may have contributed to the
success of this approach, since substitution of the RBS
with human stromal-derived factor-1 alpha (SDF-1α),
which also uses a structurally similar receptor (CXCR4),
has also been successful [6]. In contrast, attempts to make
peptide ligand substitutions in this RBS that are either dis-
similar in length or use structurally unrelated receptors
have met with limited success (i.e. see [7].
Following binding between retroviral Env glycoproteins
and their receptors, conformational changes must take
place in both the SU and TM that expose the fusion pep-
tide and enable membrane fusion to occur. H. Garoff pre-
sented work extending his recently published report [8]
showing that for γ-retroviruses this conformational
change involves SU-TM disulfide bond isomerization. The
isomerization, which is inhibited by Ca2+, results in
breakage of the SU-TM disulfide bond, the generation of
an intra-SU bond, and subsequent exposure of the TM
fusion peptide. Garoff speculated that the ability of γ-ret-
roviruses such as MLV to fuse at the cell surface, in contrast
to α-retroviruses like ALV that lack isomerization activity
and which apparently undergo pH-dependent fusion in a
subcellular compartment, is the result of this isomeriza-
tion.
Several studies have implicated amino acid changes in the
cytoplasmic domain of the MLV TM on SU conformation,
with consequent effects on viral infectivity and antibody
recognition [9,10]. Work presented by R. Montelaro dem-
onstrated that mutations in the cytoplasmic tail of the
HIV-1 TM (gp41) can also result in escape from neutrali-
zation. Importantly, at least one of these antibody-escape
mutants still retained wild-type infectivity, indicating that
sequence changes in the TM intracytoplasmic domain
should be considered in the characterization of antigenic
variants of HIV-1 that escape neutralization.
Dendritic cells express a molecule known as DC-SIGN
that binds HIV-1 particles and facilitates their transmis-
sion to susceptible target cells [11]. The mechanism by
which this molecule promotes the transfer of infectious
virions to target cells has been an active area of investiga-
tion for the past several years. Work from V. KewalRam-
ani's lab (Wu et al.) showed that DC-SIGN is able to
transfer HIV-1 infectivity in trans when expressed on some
cell types but not when expressed on others. The ability of
DC-SIGN to promote virus transfer appears to correlate
with the localization of the particles on the DC-SIGN-
expressing cell; in cells unable to mediate transfer, virions
are internalized, whereas cells able to mediate efficient
transfer retain virions at the cell surface. Wu and col-Retrovirology 2004, 1:25 http://www.retrovirology.com/content/1/1/25
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leagues also observed that binding and transmission of
HIV-1 by immature dendritic cells is Env- and DC-SIGN-
dependent, whereas virus binding by mature dendritic
cells does not require either Env on the particle or DC-
SIGN on the dendritic cell. The molecule(s) expressed on
dendritic cells that potentiate DC-SIGN-independent
virus transmission await discovery.
Post-entry events
The last two years have seen major advances in our under-
standing of the mechanisms by which cells from human
and non-human primates restrict retroviral infection. In
2002, Sheehy et al. [12] reported that the HIV-1 accessory
protein Vif interacts with the cellular cytidine deaminase
APOBEC3G. In the absence of Vif expression, APOBEC3G
is incorporated into HIV-1 virions and, during reverse
transcription in the target cell, converts cytosines to
uracils. This conversion results in the degradation of
newly synthesized DNA through the action of host gly-
cosidases and repair enzymes, and leads to G-to-A hyper-
mutation in the newly synthesized viral DNA. Vif counters
the antiviral activity of APOBEC3G by blocking its incor-
poration into virions in the producer cell. Interestingly,
Vif displays species specificity in its ability to inactivate
APOBEC3G; for example, HIV-1 Vif blocks the antiviral
activity of human but not African green monkey
APOBEC3G, and SIVagm Vif inactivates African green
monkey but not human APOBEC3G. The labs of N.
Landau and V. Pathak both reported that the determinant
of this species specificity maps to amino acid 128 of
APOBEC3G. Data in the Landau lab presentation (Schro-
felbauer et al.) suggested that the inability of HIV-1 Vif to
block the activity of African green monkey APOBEC3G
was due to a lack of binding between these two proteins,
whereas the Pathak lab (Xu et al.) reported that mutation
of residue 128 of human APOBEC3G did not prevent
binding of the mutant protein to Vif. Both labs recently
published their findings [13,14].
Since the incorporation of APOBEC3G into virus particles
is required for its antiviral activity, several groups have
focused on how this cellular protein is incorporated. The
mechanism of APOBEC3G incorporation is of particular
interest since it appears not to be specific for HIV-1 (e.g.,
human APOBEC3G is incorporated into MLV particles)
and because inhibitors that disrupt Vif's ability to block
APOBEC3G incorporation would presumably display
antiviral properties. L. Kleiman's lab (Cen et al.) reported
that APOBEC3G interacts directly with Gag in a manner
dependent on the Gag nucleocapsid (NC) domain. The
labs of W. Popik and X.F. Yu also observed that NC plays
an important role in the APOBEC3G/Gag interaction. H.
Xu from V. Pathak's group reported that mutation of NC
reduced but did not abrogate APOBEC3G incorporation
into virions. Since NC is a major determinant of RNA
packaging into virions, these data, together with the
above-mentioned finding that APOBEC3G is incorpo-
rated into MLV particles, can be rationalized by a model
that proposes an important role for RNA (either viral or
cellular) in APOBEC3G incorporation. Such a model
would also be consistent with the apparent inability of
HIV-1 to evade APOBEC3G incorporation simply by
mutation of a specific protein-protein binding site. Inter-
estingly, a study from D. Ho's lab (Simon et al.) found
that isolates of HIV-1 that are unable to block APOBEC3G
activity are relatively common in infected patients. The
authors suggested that sporadic Vif inactivation might be
a factor in promoting viral evolution in vivo since Vif-
defective variants would exhibit a higher mutation rate.
In recent years, several groups have reported that HIV-1 is
unable to efficiently infect cells from certain species of
Old World monkey (for review see [15]). The block is
imposed early post-entry, prior to reverse transcription,
and is mediated by an inhibitory factor expressed in Old
World monkey cells. The viral determinant of this restric-
tion maps to the capsid (CA) domain of Gag, making this
restriction somewhat reminiscent of the Fv1 block
described by Lilly and others decades ago [16]. J.
Sodroski's group recently published that the rhesus
macaque version of the cytoplasmic body component
TRIM5α [17] potently blocks HIV-1 infection. Presenta-
tions from the labs of J. Sodroski (Stremlau et al.) and P.
Bieniasz (Hatziioannou et al.) reported that Ref1 and
TRIM5α are species-specific variants of TRIM5α; this find-
ing has now been published [18]. This factor is quite dis-
tinct from Fv1, which bears sequence homology to MLV
CA [19]. A. Lassaux (from the Battini and Sitbon labs)
reported that Fv1 and Ref1 recognize different amino acid
combinations within the same 100 amino acid determi-
nant of the MLV CA. Hatziioannou et al. also described
their results on characterizing the ability of human- and
monkey-derived TRIM5α's to block the entry of a panel of
retroviruses. D. Sayah from J. Luban's lab provided a pre-
view of the now-published paper [20] reporting the
intriguing finding that in owl monkey cells, the post-entry
block to HIV-1 infection is conferred by a TRIM5α-cyclo-
philin A fusion protein. In another presentation focused
on post-entry blocks to retroviral infection, V. KewalRam-
ani's lab (Martin et al.) reported that overexpression of a
truncated form of an RNA binding protein that is a com-
ponent of the poly A machinery blocks an early stage of
the HIV-1 infection process without disrupting MLV infec-
tivity.
J. Young (Narayan and Young) reported the development
of a cell-free uncoating assay that will likely prove useful
in defining the role of cellular factors in stimulating or
blocking early post-entry steps in the replication cycle.
Avian sarcoma/leukosis virus (ASLV) particles can beRetrovirology 2004, 1:25 http://www.retrovirology.com/content/1/1/25
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trapped in endosomes when cells expressing a GPI-linked
version of the ASLV receptor are infected in the presence
of NH4Cl. The virus-containing endosomes can then be
isolated; upon removal of the NH4Cl in vitro, fusion and
reverse transcription take place in a manner dependent
upon ATP hydrolysis and the presence of cellular factors.
This cell-free uncoating assay can be adapted to other
viruses (e.g., HIV-1) by pseudotyping with the ASLV Env
glycoprotein. The authors reported that monkey cell
restriction factors, and cyclosporin A (which blocks cyclo-
philin A incorporation into HIV-1 particles), inhibit
reverse transcription in this system, suggesting that it
faithfully recapitulates certain key aspects of uncoating in
infected cells. Some of the data in this presentation were
recently published [21].
Assembly and Release
Major developments have taken place in the past several
years in our thinking about the location in the host cell at
which retrovirus assembly takes place, and the mecha-
nism by which Gag proteins target the subcellular site of
assembly. Until recently, it was felt that viruses that follow
the type C assembly pathway [including the lentiviruses
(e.g., HIV-1), δ-retroviruses (e.g., HTLV-1), γ-retroviruses
(e.g. MLV), etc.] assemble at the plasma membrane. How-
ever, it has long been recognized that in some cases (for
example, HIV-1 in macrophages) assembly and budding
take place at an intracellular compartment. Several groups
have recently demonstrated that this compartment is the
late endosome or multivesicular body (MVB), and it now
appears that while the plasma membrane likely represents
the predominant site of assembly for these viruses, Gag
can also target and assemble in an endosomal compart-
ment in a variety of cell types. M. Resh's lab (Perlman and
Resh) used the tetracyteine/biarsenical live-cell labeling
system reported by Gaietta et al. [22] to follow Gag traf-
ficking relatively early (1–4 hrs.) post-synthesis. Their
results suggest that Gag may first localize to secretory lys-
osomes and then subsequently "ride" these vesicles to the
plasma membrane. M. Thali's lab recently reported that a
significant fraction of HIV-1 Gag colocalizes with late
endosomal markers both at intracellular membranes and
at the plasma membrane [23]. Together with D. Ott's lab
(Nydegger et al.), they have also started using the tetra-
cysteine/biarsenical technology to analyze Gag localiza-
tion. Like the Resh lab, they observe some association of
Gag with late endosomal/MVB membrane, but a signifi-
cant fraction of newly synthesized Gag appears to associ-
ate directly with discrete plasma membrane
microdomains. P. Spearman's lab (Dong et al.) reported
interesting findings implicating the AP-3 clathrin adaptor
protein complex (which among other things regulates
CD63 trafficking) in HIV-1 Gag targeting. They observed
that the δ subunit of AP-3 interacts with the MA domain
of Gag and that either overexpression of an N-terminal δ
subunit fragment or siRNA knockdown of AP-3 δ subunit
expression inhibits HIV-1 release.
H. Wang from L. Mansky's group observed that HTLV-1
assembly, like that of HIV-1, can take place in the MVB.
Interestingly, while in HeLa cells HTLV-1 assembly
appears to occur primarily at the plasma membrane,
mutational disruption of the Pro-Thr-Ala-Pro (PTAP) late
domain results in accumulation of virus particles in the
MVB, consistent with published results (e.g., [24]). T.
Hope's lab (Gomez and Hope) confirmed the finding [25]
that HIV-1 mutants lacking the p6 late domain still assem-
ble in MVBs in macrophages, indicating that interactions
between p6 and cellular host factors (e.g., Tsg101) are not
required for MVB localization. Reports from the labs of D.
Muriaux (Grigorov et al.) and F.-L. Cosset (Sandrin et al.)
suggested that interactions between MLV Gag and Env
may occur in an intracellular compartment and that this
interaction might influence both Gag trafficking and Env
incorporation into virions. Some of this work has now
been published [26].
A study from the Freed lab (Ono and Freed) examined the
possibility that the phosphoinositide phosphatidylinosi-
tol-(4,5)-bisphosphate (PI(4,5)P2) plays a role in Gag tar-
geting. This lipid is of interest since it is involved in the
trafficking of a variety of cellular proteins that, like many
retroviral Gag proteins, contain a basic membrane bind-
ing domain. Furthermore, work from A. Rein's lab [27]
has shown that, in vitro, HIV-1 Gag binds molecules struc-
turally related to phosphoinositides. A. Ono used enzy-
matic approaches to perturb cellular PI(4,5)P2 levels in
virus-expressing cells and observed that Gag targeting and
virus assembly were shifted from the plasma membrane
to intracellular compartments. These results indicate that
cellular PI(4,5)P2 plays a role in directing Gag to the
plasma membrane.
Work from J. Lingappa's lab previously suggested the
involvement of the cellular RNase L inhibitor HP68 in
HIV-1 assembly [28]. This work was extended at the meet-
ing by Dooher et al., who showed that HP68, Gag, and
genomic RNA colocalize in virus-producing cells. The cel-
lular protein nucleolin was also found to be a component
of the Gag/HP68 complex.
Novel findings relating to the regulation of foamy virus
(FV) release were reported by the Lindemann lab. FVs are
unusual among retroviruses in that Env glycoprotein
expression plays a critical role in particle release. The
leader peptide of FV Env, which is generated by a cleavage
event during Env trafficking to the plasma membrane and
is incorporated into particles, seems to play an important
role in the budding process. Lindemann et al. reported the
identification of ubiquitylated forms of the leader pep-Retrovirology 2004, 1:25 http://www.retrovirology.com/content/1/1/25
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tide; suppression of these ubiquitylated forms markedly
stimulated subviral particle release. These results suggest
that ubiquitylation of the FV Env leader peptide modu-
lates the ratio of particle vs. subviral particle budding.
Progress continues to be made in visualizing retrovirus
assembly and release in real time in living cells. In addi-
tion to use of the tetracyteine/biarsenical live-cell labeling
system described above, B. Muller from H.-G. Krausslich's
lab discussed the development of an infectious HIV-1
derivative containing a GFP insert near the C-terminus of
MA. This derivative produces particles with wild-type
morphology; however, release kinetics are impaired.
While the Gag-GFP virus is poorly infectious, infectivity
can be restored upon coexpression with wild-type HIV-1.
This Gag-GFP HIV-1 derivative should be useful for both
assembly/release and post-entry studies. In a presentation
from the labs of V. Vogt and W. Webb, D. Larson
described the use of correlated fluorescence microscopy
and scanning electron microscopy to visualize Rous sar-
coma virus (RSV) budding in real time using a GagGFP
derivative.
Major advances have been made in the past three years in
elucidating the host cell machinery required for the
release of retrovirus particles from infected cells [29,30]. It
is now well accepted that retroviruses use their late
domains to commandeer machinery that normally plays
a central role in promoting the budding of vesicles into
the MVB. This machinery includes the so-called "class E
Vps" factors originally identified in yeast as being crucial
for MVB biogenesis [31]. Many of these class E Vps pro-
teins are found in three multisubunit complexes known as
ESCRT-I, -II, and -III. Retroviral late domains come in
three flavors: Pro-Thr/Ser-Ala-Pro [P(T/S)AP], Pro-Pro-x-
Tyr (PPxY), and Tyr-Pro-Asp-Leu (YPDL). HIV-1 release is
controlled predominantly by a P(T/S)AP-type late
domain; many retroviruses, including MLV and RSV, con-
tain PPxY late domains; and equine infectious anemia
virus (EIAV) harbors a YPDL late domain. Several retrovi-
ruses [e.g., Mason-Pfizer monkey virus (M-PMV) and
HTLV-1] encode both P(T/S)AP and PPxY late domains.
In addition to its P(T/S)AP motif, HIV-1 contains a sec-
ondary YPDL-related sequence whose role in HIV-1
release remains to be defined. It is now well established
that the P(T/S)AP motif interacts with the ESCRT-I com-
ponent Tsg101. Recent data from several labs (those of H.
Gottlinger, W. Sundquist, and P. Bieniasz) have strongly
suggested that AIP1 (also known as ALIX) is the host fac-
tor with which YPDL interacts. There is less certainty
about the identity of the biologically relevant PPxY-inter-
acting protein. PPxY motifs in cellular proteins often
interact with WW domains, and several PPxY-containing
retroviral Gag proteins have been reported to bind the
ubiquitin ligase Nedd4 (or related proteins), which con-
tains a series of centrally located WW domains. P.
Bieniasz's lab (Martin-Serrano et al.) reported at the meet-
ing that MLV Gag binds the Nedd4-related proteins
WWP1 (which has also been shown to associate with
HTLV-1 Gag [32]), WWP2 and ITCHY. The extent to
which binding to these proteins was reduced by muta-
tions in the PPPY motif correlated with the severity of the
budding defect induced by the mutations. The authors
also observed that WWP1 localizes to aberrant endosomes
induced by expression of a dominant-negative Vps4 in a
manner dependent on the ubiquitin ligase (or HECT)
domain, suggesting that the HECT domain may link
WWP1 (and consequently Gag) to the class E Vps machin-
ery. J. Leis's lab previously reported that overexpression of
the WW domain-containing region from a chicken
Nedd4-like protein inhibited RSV particle production. At
this year's meeting, this work was extended (Vana et al.)
by showing that in cells overexpressing this WW domain-
containing fragment RSV virions accumulated in intracel-
lular inclusion bodies. Interestingly, V. Vogt's lab (John-
son et al.) found that overexpression of the C-terminal
domain of Tsg101 formed aggresome-like structures that
trapped HIV-1 Gag.
In yeast, ESCRT-I contains three protein components:
Vps23 (the yeast homolog of Tsg101), Vps28 and Vps37.
In mammalian cells, only the Vps23 and Vps28 homologs
had been identified. At this year's meeting, M. Stuchell
from W. Sundquist's lab reported the cloning of human
Vps37. As in yeast, human Vps37 binds Tsg101 and is
present along with Tsg101 and Vps28 in a high molecular
weight ESCRT-I complex. Much of this work has recently
been published [33], as have similar results from H. Sten-
mark's lab [34]. Further illustrating the importance of
ESCRT-I in HIV-1 budding, fusion of Vps37 to the C-ter-
minus of Gag reverses the release defect imposed by PTAP
deletion [33]. Y. Yardin's lab (Amit et al.) described the
identification of an E3 ubiquitin ligase (termed Tal, for
Tsg101-associated ligase) that binds the N-terminal UEV
domain of Tsg101 and apparently regulates its activity.
This work has also recently been published [35].
M. Palmarini's lab (Mura et al.) described a novel type of
retroviral interference that operates at the level of virus
assembly and release. The sheep genome harbors a
number of copies of endogenous retroviruses closely
related to the pathogenic exogenous β-retrovirus
Jaagsiekte sheep retrovirus (JSRV). One of these endog-
enous retroviruses (enJS56A1) displays a defect in assem-
bly/release. EM analysis indicates that enJS56A1 particles
form large perinuclear aggregates; these appear to trap
JSRV particles intracellularly when enJS56A1 and JSRV are
coexpressed. The authors speculate that enJS56A1 may
have helped protect sheep from infection with related,Retrovirology 2004, 1:25 http://www.retrovirology.com/content/1/1/25
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exogenous retroviruses during evolution. Much of this
study has recently been published [36].
It has been known for many years that several retroviruses
express two forms of Gag: a conventional version and a
larger, glycosylated form referred to as glycoGag. Gly-
coGag is synthesized using an alternative, upstream initi-
ation codon, and unlike its smaller counterpart it is
transported to the plasma membrane through the secre-
tory pathway. H. Fan's lab (Low et al.) reported at this
year's meeting that a packaging cell line that expresses Gag
without glycoGag produces tube-shaped particles at the
cell surface. This apparent assembly defect was corrected
by coexpression of glycoGag. The expression of glycoGag
increased both virus yield and infectivity. These results
suggest that glycoGag may function, in a manner that
remains to be elucidated, in regulating proper virus
assembly and release.
Integration
Retroviral preintegration complexes (PICs) and the inte-
grase (IN) enzyme itself, interact with a variety of host fac-
tors during nuclear import of the PIC and integration of
the newly synthesized viral DNA into the host cell chro-
mosome. One such host factor, lens epithelium-derived
growth factor (LEDGF/p75), was recently reported to bind
HIV-1 IN [37,38]. Several presentations at this year's
meeting provided varied and conflicting results regarding
the role of LEDGF/p75 in the integration process. S. Emil-
iani reported data from a collaboration between the labs
of R. Benarous and Z. Debyser showing that knockdown
of LEDGF/p75 expression using siRNA in HeLa P4 cells
inhibited HIV-1 replication without affecting the import
of IN to the nucleus. The Q168L mutation in HIV-1 IN
abolished both virus replication and the interaction
between IN and LEDGF/p75. Busschots from the Debyser
lab showed that the interaction of LEDGF/p75 with IN
increased the affinity of IN for DNA. Based on these data,
it was postulated that LEDGF/p75 may play a role in teth-
ering IN to chromosomal DNA. E. Poeschla's lab (Llano et
al., also see [39]) observed that endogenous LEDGF/p75
co-immunoprecipitated with both HIV-1 and FIV IN. Sta-
ble knock-down of LEDGF/p75 expression in 293T cells
induced a redistribution of both HIV-1 and FIV IN from
the nucleus to the cytoplasm but apparently did not affect
nuclear import of HIV-1 or FIV PICs since lentiviral vector
infectivity was not reduced under these conditions. Fur-
thermore, stable knock-down of LEDGF/p75 expression
in the Jurkat T-cell line did not affect HIV-1 replication.
However, LEDGF/p75 was found to be a component of
lentiviral PICs. The authors concluded that LEDGF/p75 is
not required for lentiviral integration but advanced the
hypothesis that it might play a role in target site selection.
Vandekerckhove and colleagues from the Debyser lab
reported that stable knock-down of LEDGF/p75 expres-
sion in HeLa P4 or MOLT cells delayed HIV-1 replication
but did not diminish infectivity mediated by a VSV-G
pseudotyped lentiviral vector. The authors controlled for
non-specific siRNA effects by using double mismatched
siRNA. Results from A. Engleman and coworkers (Vande-
graaff et al.) raised further questions concerning the role
of LEDGF/p75 in HIV-1 integration. They observed that
while two LEDGF/p75 siRNAs reduced LEDGF/p75 pro-
tein levels, only the one originally described by the
Debyser lab impaired HIV-1 infectivity. This infectivity
defect could not be reversed by partially restoring LEDGF/
p75 expression. Based on these results, the authors cau-
tioned that the effect of LEDGF/p75 siRNA on HIV-1
infectivity may be due to non-specific effects not directly
related to LEDGF/p75. Clearly, additional studies need to
be performed to clarify the role of LEDGF/p75 in lentiviral
integration.
A number of presentations focused on the target site spe-
cificity of retroviral (or retrotransposon) integration. Dif-
ferent retroviruses and retroelements display strong
preferences in selecting their target sites in the genomes of
their host cells (for review see [40]). For example, the Ty1
and Ty3 retrotransposons integrate predominantly
upstream of Pol III-transcribed genes; the Tf1 retrotrans-
poson selects sequences upstream of Pol II-transcribed
genes; HIV-1 tends to integrate in actively transcribed
regions; and MLV prefers to integrate in the promoters of
active genes. At this year's meeting, A. Narezkina from R.
Katz's and A. Skalka's lab, and R. Mitchell from F. Bush-
man's group, both described the results of genome-wide
analyses of ASLV integration sites. They observed that,
unlike MLV, this avian retrovirus does not prefer to inte-
grate at transcription start sites, and unlike HIV-1 does not
display a strong preference for highly active genes. Both
groups did observe a relatively modest tendency for inte-
gration within genes. H. Levin's group (Kelly et al.)
extended their previous work on Tf1 integration. Using a
target plasmid containing a single gene, they observed
that nearly all integration events took place in the gene's
promoter region. Interestingly, the integration sites dis-
played a periodic pattern in which integrated copies of Tf1
were separated by around 30 nucleotides. This targeting
appeared to be dependent on promoter activity. Kelly and
coworkers speculated that the chromodomain in the Tf1
IN binds histones and regulates integration into specific
targets in a promoter-positioned nucleosome. Holman
and Coffin reported on the analysis of base preferences
immediately surrounding integrated HIV-1 proviruses.
Using a large amount of data derived from previously
reported integration sites, the authors observed strong
base preferences within seven residues at either end of
integrated proviruses. The presentation emphasized that
HIV-1 integration shows target preferences on both a
macro scale (as noted above) and on a microscale, involv-Retrovirology 2004, 1:25 http://www.retrovirology.com/content/1/1/25
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ing the residues immediately adjacent to the integration
site.
M. Katzman's lab (Konsavage et al.) reported an interest-
ing RSV IN mutant that displayed enhanced 3'-end
processing activity but impaired DNA joining. The
authors speculated that RSV IN has evolved suboptimal
processing activity to allow it to catalyze DNA joining.
R. Craigie's lab previously reported that a protein termed
"barrier-to-autointegration factor" (BAF) is a component
of the MLV preintegration complex and that this factor
enhances intermolecular integration reactions and blocks
intramolecular integration (autointegration) [41]. At this
year's meeting, Suzuki and Craigie extended this work by
showing that BAF interacts with an inner nuclear mem-
brane protein, lamina-associated polypeptide 2α
(LAP2α). LAP2α is a component of the MLV preintegra-
tion complex and knockdown of its expression inhibits
MLV replication.
Reverse Transcription
A number of studies over the years have demonstrated
that retroviral NC proteins possess nucleic acid chaperone
activity that plays an important role in various aspects of
reverse transcription (for review, see [42]). Several presen-
tations focused on this activity of NC. Work from J. Levin's
lab (Guo et al.) demonstrated that in an in vitro assay that
models minus-strand transfer, NC alone is able to catalyze
the removal of small 5' terminal genomic RNA fragments,
which remain annealed to a minus-strand strong-stop
DNA. Strand transfer product increased with increasing
NC, and in the presence of NC, strand transfer product
was generated even when reverse transcription was cata-
lyzed by an RNase H-deficient RT. The NC zinc fingers
appeared to be critical for this activity. These results sug-
gest an important role for NC nucleic acid chaperone
activity in removing terminal RNA fragments annealed to
minus-strand strong-stop DNA following primary cleav-
age by RNase H. By examining reverse transcription in
infected cells, R. Gorelick's lab (Thomas et al.) observed
that mutations in the first zinc finger of NC strongly inter-
fered with the progression of reverse transcription and
impaired virus infectivity. The authors speculated that
reduced binding of NC to the viral DNA allows cellular
enzymes (nucleases and ligases) to modify the viral DNA
ends thereby interfering with integration.
Reverse transcription is initiated by a host cell-derived
tRNA bound to the primer binding site (PBS) near the 5'
end of the viral genome. Retroviruses are selective in their
utilization of host tRNAs; HIV-1, for example, specifically
primes reverse transcription with a tRNAlys3. The selectiv-
ity for particular tRNAs results from interactions between
the tRNA and the PBS and it has been proposed by B.
Berkhout and colleagues that a second motif in the viral
RNA, termed the primer-activation signal (PAS), also
forms specific contacts with the tRNA. Berkhout's lab
(Abbink et al.) reported at this year's meeting that, by
mutagenesis of the PBS and PAS, HIV-1 primer utilization
could be shifted from tRNAlys3 to tRNAlys1,2. Such mutants
replicated poorly but could adapt during long-term pas-
saging. In one case, adaptation evidently occurred
through optimization of the putative PAS. Interestingly, a
single amino acid change in the RNase H domain of RT
also arose during adaptation, suggesting a possible role
for RT in selective primer utilization.
While PCR techniques allow the progression of viral DNA
synthesis to be monitored post-infection, it has not been
possible to follow reverse transcription in a strand-specific
fashion in infected cells. D. Thomas from V. Pathak's lab
reported the development of a strand-specific amplifica-
tion assay that uses so-called "padlock" probes – long sin-
gle-stranded oligonucleotides that hybridize with their
target sequence simultaneously at their 5' and 3' ends. Fol-
lowing hybridization, the ends of the padlock probes are
ligated to form circles that are amplified and detected by
real-time PCR. This assay, which allows specific steps in
reverse transcription to be measured quantitatively in a
strand-specific manner, should be very useful for address-
ing a number of questions regarding the kinetics of reverse
transcription and the efficiency of this process under a
variety of conditions.
F. Maldarelli described the results of studies conducted
with S. Palmer, J. Coffin and colleagues aimed at charac-
terizing the evolution of HIV-1 populations in vivo. The
authors monitored genetic variation in cohorts of drug-
naïve and drug-resistant patients by analyzing individual
pro-pol sequences. In both drug-naïve and drug-resistant
patients, they observed little change in virus population
structure over several years, implying that the replicating
population is relatively large. Interestingly, recombina-
tion rates appeared to be very high regardless of levels of
viremia, suggesting the presence of a substantial number
of multiply infected cells even at low viral loads. The
results emphasize the importance of recombination in
generating viral diversity in vivo.
Pathogenesis
The keynote speaker at this year's meeting was Neal Cope-
land, who presented important findings from his and
Nancy Jenkins' lab regarding the use of high through-put
analysis to map retroviral integration sites in tumors
induced by MLVs. This rapidly developing approach is
being used by a number of groups to elucidate cancer gene
pathways [43-46], and to define retroviral integration site
preferences. The Jenkins and Copeland labs have used
infection of various hematopoietic stem cells followed byRetrovirology 2004, 1:25 http://www.retrovirology.com/content/1/1/25
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transplantation into lethally irradiated mice to identify
not only novel proto-oncogenes, but also cooperating
cancer genes, tumor suppressors, and genes involved in
stem cell transformation and immortalization. While this
technique is currently applicable only to hematopoietic
lineage cells, current research in the Jenkins and Copeland
labs is testing whether integration by transposable ele-
ments in other cell types can be used to identify similar
genes and pathways in solid tumors.
In contrast to the majority of leukemia-inducing retrovi-
ruses in non-human species, most of which cause cancer
by insertional mutagenesis, HTLV-I encodes accessory
proteins, such as Tax, with known transforming activity.
There were several talks at the meeting describing new
accessory proteins that may also play a role in cell regula-
tion. Two talks focused on the protein p12I, which is tar-
geted to the endoplasmic reticulum/Golgi of infected cells
and decreases MHC class I trafficking to the cell surface. R.
Fukomoto from G. Franchini's lab presented data that
p12I decreases activation of the transcription factor NFATI
in T cells by binding to LAT and inhibiting T-cell receptor
signaling. In contrast, M. Lairmore presented data that
p12I expression in Jurkat cells results in ~20-fold activa-
tion of NFAT-dependent gene expression in a calcium-
dependent manner (Kim and Lairmore). These authors
also demonstrated that p12I acts in the endoplasmic retic-
ulum to activate calcium-mediated T-cell activation dur-
ing the early stages of infection, apparently through an
interaction with calcineurin. These studies suggest a
prominent role for p12I in common T cell activation path-
ways critical to the establishment of a persistent infection.
Another protein, p13II, which was described by V. Cimi-
nale (Silic-Benussi et al.), is localized to the inner mito-
chondrial membrane and induces changes in Ca2+ and K+
permeability. In culture, p13II reverses the morphological
transformation of rat embryo fibroblasts expressing c-Myc
and Ha-Ras and decreases their ability to form tumors in
nude mice. There was speculation that HTLV-I encodes
p13II to counteract the growth-inducing properties of the
other viral accessory proteins (such as Tax) that are
required for establishment of infection, thereby allowing
the virus to persist in infected individuals.
In a theme that echoed in several of the simple retrovirus
talks, V. Armbruester from the Mueller-Lantzsch labora-
tory reported on a novel protein generated by alternative
splicing of the envelope gene of the HERV-K endogenous
retrovirus. The transcript for this protein, np9, is highly
expressed in mammary carcinomas and germ cells, and
the gene product binds to the LNX protein, which is a lig-
and of Numb and targets it for proteasomal degradation.
Since LNX/Numb/Notch is a known transformation path-
way in tumors, Armbruester speculated that np9 may play
a role in tumorigenesis by sequestering LNX, thereby sta-
bilizing Numb.
RNA transcription, processing, export and 
packaging
This session surveyed new findings on retroviral splicing,
nuclear retention and export, translation and packaging. J.
Madsen and M. Stoltzfus evaluated the role of an exonic
splicing silencer (ESS) on HIV-1 replication in cultured T
cells. An HIV-1 mutant with ESS substitutions displays a
replication-defective phenotype that correlates with
increased viral RNA splicing. This mutant was subjected to
long-term passage and the viruses that emerged contained
second-site reversions in splice sites flanking the exon
containing the mutated ESS. Stoltzfus speculated that
strains that do not contain the ESS maintain balanced
expression of their viral genome by a novel, unknown
mechanism.
A. Lever's lab (Poole et al.) described confocal microscopy
and fluorescence resonance energy transfer (FRET) analy-
sis of the interaction between HIV-1 Gag and its cognate
genomic RNA. Using biotinylated probes to the full-
length, unspliced RNA, he described an initial perinuclear
co-localization between Gag and genomic RNA that sub-
sequently shifted to the plasma membrane. Mutation of
the Ψ packaging signal partially disrupted the perinuclear
and plasma membrane colocalization.
J. Dudley's lab (J. Mertz et al.) described a new MMTV
gene that encodes a viral RNA transport protein generated
by alternative splicing of the env gene. The gene was des-
ignated rem, (for RNA export protein of MMTV RNA). Its
product stimulated nucleocytoplasmic transport of the
unspliced MMTV transcript, in a manner similar that of
the Rec protein of HERV-K [47,48]. This finding indicates
that MMTV encodes at least three accessory genes (encod-
ing dUTPase, superantigen, and Rem) in addition to the
standard retroviral genes (gag, pol, and env). The Dudley
group suggested that since MMTV exhibits a complex
genetic structure it should be reclassified as a complex ret-
rovirus.
K. Boris-Lawrie (Roberts et al.) presented genetic and bio-
chemical data showing that the R-U5 region of SNV RNA
adopts a stem-loop structure that stimulates cap-depend-
ent translation. RNA affinity and proteomic analysis
showed that RNA helicase A (RHA) bound to wild-type
RNA but not to mutants containing substitutions in this
structure. RHA interaction with SNV R-U5 stimulated
translation of unspliced HIV-1 reporter mRNA. Boris-
Lawrie speculated that this could occur by rearrangement
of intramolecular RNA interactions that disrupt the pack-
aging signal, thus facilitating mRNA translation.Retrovirology 2004, 1:25 http://www.retrovirology.com/content/1/1/25
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In vivo, only a fraction of HTLV-infected cells actively
expresses viral RNA, leading to speculation that the virus
negatively regulates gene expression. P. Green (Younis et
al.) described a new role for HTLV-1 and -II accessory pro-
teins p30 and p28, respectively, in negatively regulating
virus production during chronic infection. Tax/Rex
expression was inhibited upon ectopic expression of p28
by a mechanism that involved nuclear retention of the
mRNA. Analysis of RNAs bearing a luciferase reporter
gene showed that the 3' splice junction was sufficient to
confer this nuclear retention. From this work and the
studies from the Franchini and Lairmore labs described
above, it is clear that HTLV-1 has evolved to regulate its
expression in infected cells, thereby evading immune rec-
ognition and promoting viral persistence.
Antivirals
As in previous years, there was a strong emphasis on the
development of antiviral agents that interfere with reverse
transcription. However, noteworthy progress was also
reported in efforts to target a number of additional steps
in the replication cycle.
S. Sarafianos reported data from E. Arnold's lab (Himmel
et al.) on the structure of HIV-1 RT in a complex with an
RNase H inhibitor. Interestingly, the binding site of the
compound is quite distant (>40 Angstroms) from the
RNase H active site and partially overlaps the NNRTI
binding pocket. These results raise the intriguing possibil-
ity that compounds could be designed that simultane-
ously act as RNase H inhibitors and as NNRTIs. M. Miller's
lab (Shaw-Reid et al.) performed in vitro assays to examine
the effect of RT polymerase inhibitors on RNase H activity.
They observed that NNRTIs actually increased RNase H
activity; structural studies suggested that this enhance-
ment was due to greater accessibility of the DNA/RNA
duplex by RNase H. Although a diketo acid RNase H
inhibitor displayed decreased potency in the presence of
an NNRTI, the diketo acid and NNRTI synergistically
inhibited reverse transcription overall.
C. Wild, E. Freed, and colleagues, and independently C.
Aiken's lab, previously reported that a dimethyl succinyl
betulinic acid derivative (referred to as PA-457 or DSB)
potently blocks HIV-1 infectivity by specifically disrupting
the cleavage of the CA precursor (composed of CA and
spacer peptide SP1) to mature CA [49,50]. The block to
CA-SP1 processing prevents proper core condensation in
virions released from PA-457-treated cells. Interestingly,
HIV-2 and SIV are insensitive to PA-457. This work was
extended by the labs of C. Wild and E. Freed (F. Li et al.)
to demonstrate that the determinant of PA-457 activity
maps to the N-terminus of SP1. In addition, (Adamson et
al.) the passaging of HIV-1 at sub-optimal concentrations
of PA-457 led to the appearance of PA-457-resistant vari-
ants that contain mutations in the C-terminus of CA or
the N-terminus of SP1.
A. Lever's lab (Brown et al.) described their efforts to
inhibit HIV-1 replication using oligonucleotides that tar-
get the viral genome. The authors observed that oligos tar-
geting the packaging signal (specifically stem-loops 2 and
3) disrupt Gag binding and reduced virus infectivity. T.
Murakami and coworkers reported the development of an
orally bioavailable compound that binds the HIV-1 chem-
okine coreceptor CXCR4. In culture, the compound
potently inhibits infection by HIV-1 isolates that use
CXCR4 as a coreceptor, but, as expected, do not block
infection by strains that exclusively use CCR5 as a corecep-
tor. The compound suppressed HIV-1 infection in the hu-
PBL-SCID mouse model. The results of this study suggest
that this CXCR4 antagonist could potentially be an effec-
tive drug in infected humans.
It has been suggested that most virus originating in the
central nervous system (CNS) derives from long-lived
cells (e.g., macrophages) that would continue to produce
virus for a significant period of time after the initiation of
antiretroviral therapy. According to this model, CNS-
derived virus should decay more slowly following the
onset of therapy relative to virus derived from the blood.
In the last presentation of the conference, data were pre-
sented from R. Swanstrom's lab (Harrington et al.)
obtained from a study of HIV-1 population dynamics in
cerebrospinal fluid (CSF) immediately following the initi-
ation of antiretroviral therapy. Virus isolates in the CSF
apparently derive from both the CNS and the blood
plasma. Interestingly, using heteroduplex tracking assays,
the authors observed that within the first several days fol-
lowing the initiation of therapy CNS-derived isolates in
the CSF decline with similar kinetics to isolates shared
with the blood, suggesting that virus from both compart-
ments is produced by cells with a short life span.
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